Ingredient linked to DEMENTIA found in popular food product used by over 200m Americans
Ziploc, the popular brand of food bags and containers used by over 200 million Americans, is now at the center of a troubling health controversy.
A class-action lawsuit filed in California accuses the maker of Ziploc, of misleading consumers about the safety of its microwave-safe bags and containers.
The complaint alleges that the plastic in Ziploc products may release harmful microplastics , potentially exposing millions to toxins over time.
Microplastics are tiny plastic fragments —less than 5 millimeters in size—linked to cancer, cardiovascular disease, and reproductive problems.
These particles can enter our food, water, and even the air as plastic products break down.
The 51-page lawsuit claims that Ziploc bags and containers, marketed as 'Microwave Safe' and suitable for freezer use, fail to warn consumers that the products may release microplastics when used as intended.
The complaint specifically mentions Ziploc Freezer Bags, Slider Freezer Bags, Slider Storage Bags, and Ziploc Containers.
'The 'Microwave Safe' and 'Freezer' labels create a false sense of security,' the lawsuit states. 'The company omits crucial information that these products release microplastics when microwaved or frozen as directed.'
DailyMail.com has contacted S.C. Johnson for comment.
The lawsuit argues that this omission isn't just misleading, but it means the products fail at their basic purpose.
'The products fail to provide a reliable method for food storage and preparation without exposing users to material risk,' the complaint states.
Filed by California resident Linda Cheslow, the suit claims that the containers labeled 'Microwave Safe' and 'Freezer' are made from polyethylene and polypropylene.
Polyethylene and polypropylene are common types of plastic that can break down into microplastics, and both are used in food packaging.
'Scientific and medical evidence shows these materials release microplastics when microwaved or frozen—making them fundamentally unsafe for those uses,' the lawsuit claims.
'Because of the defendant's false claims, people have unknowingly exposed themselves and their families to harmful microplastics during everyday kitchen activities.'
The lawsuit accuses S.C. Johnson of violating consumer trust by marketing food-safe containers while hiding known health risks.
'The company exploits consumer expectations by failing to disclose that its products release microplastics into food when microwaved or frozen,' the complaint adds.
It also claims that Ziploc bags labeled 'Microwave Safe' can release up to 4.22 million microplastic and 2.11 billion nanoplastic particles per square centimeter of plastic within just three minutes of microwave heating.
The 'Freezer' label, the suit says, misleads consumers into thinking the products are safe for low-temperature food storage without risk.
The complaint further cites studies showing a 50 percent increase in microplastics found in brain samples from 2016 to 2024, suggesting these particles accumulate in the body over time.
Polypropylene microplastics were also found in bone marrow, indicating they can penetrate deep into human tissues.
Scientists found that human brain samples contained between seven and 30 times more microplastics than livers or kidneys, with higher levels reported in individuals with dementia.
Both liver and brain samples from 2024 showed significantly more microplastics than those from 2016.
S.C. Johnson responded with a statement denying the allegations: 'We believe Ziploc products are safe when used as directed and that these claims are without merit.'
Rubbermaid, another major brand named in related concerns, is also facing criticism as toxicologists highlight issues with heat-related plastic breakdown and chemical leakage.
In the lawsuit against S.C. Johnson, the plaintiff argues that the class should include all consumers nationwide who purchased the products within the statute of limitations.
The complaint requests that the last four years be used to define this period for California consumers.
Plastic food containers have long been popular in American homes because they are affordable, convenient, and durable. However, public opinion is shifting as more research links plastic exposure to serious health risks.
Class members who join the lawsuit are eligible to receive an equal share of any settlement.
There is growing pressure on the Food and Drug Administration to update its standards for microwave-safe labeling.
Critics say current regulations are outdated and don't adequately address long-term chemical exposure or how these products are actually used.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
6 hours ago
- Daily Mail
EXCLUSIVE Just one glass of America's favorite drink 'turbocharges' risk of deadliest form of colon cancer, doctors warn
For many Americans, cracking open a soda is a small daily indulgence — a fizzy treat paired with an otherwise balanced lifestyle. But a new study suggests that even this seemingly innocent habit could be turbocharging one of the deadliest forms of cancer striking young people today. Your browser does not support iframes.
Daily Mirror
7 hours ago
- Daily Mirror
Counting calories and yo-yo diets could increase risk of depression, say experts
Eating less of a bad diet is not going to boost your mental health unless you change what you eat, research suggests after a study showed men are vulnerable to negative impact of 'restrictive eating' Counting calories and yo-yo dieting could increase your risk of depression, new research suggests. Experts say eating healthy whole foods rather than processed foods might be more important than focusing only on cutting down on calories. The study of 28,500 Americans suggests men are particularly "vulnerable" to the negative effects of 'restrictive eating' due to a lack of essential nutrients. The findings, published in BMJ Nutrition Prevention and Health, contradict previous studies which found low-calorie diets improved depressive symptoms. However researchers said earlier controlled trials included tailored and balanced diet programmes that may not be the same as the calorie counting diets people realistically follow in everyday life which contain the same processed foods. Study author Dr Venkat Bhat, of the University of Toronto, Canada, said worsening depressive symptoms could be caused by a failure to lose weight or "weight cycling" - losing weight and then putting it back on. He said: 'Real-life calorie-restricted diets and obesity often result in nutritional deficiencies - particularly in protein, essential vitamins/minerals - and induce physiological stress, which can exacerbate depressive symptomatology." Canadian researchers analysed data on 28,525 people who took part in the US National Health and Nutrition Examination Survey (NHANES) and had completed a health questionnaire relating to depressive symptoms, which gave them a score based on severity. Some 8% of those studied had reported depressive symptoms, while 33% were overweight and 38% were obese. Most said they were not on a specific diet, while 2,206 were restricting calories. Some 859 were on a "nutrient-restrictive" diet, low in fat, sugar, salt, fibre or carbohydrate, and 631 were on diets tailored for the likes of diabetes. Questionnaire scores for depressive symptoms, such as a low mood, low energy and sleep disturbances, were higher among those restricting calories compared to those who reported not being on a diet at all. The research paper concluded: "Numerous studies have consistently focused on 'healthy' versus 'unhealthy' diets. They have shown that 'healthy' diets rich in minimally processed foods, fresh fruits and vegetables, whole grains, nuts, seeds, lean proteins and fish have been linked to a lower risk of depression. "In contrast, an 'unhealthy' diet dominated by ultra-processed foods, refined carbohydrates, saturated fats, processed meats and sweets is associated with an increased risk of depressive symptoms.' Researchers said restricting calories can lead to deficiencies in protein, vitamins and minerals which puts the body under stress. Professor Sumantra Ray, chief scientist and executive director of the NNEdPro Global Institute for Food, Nutrition and Health, which co-owns the BMJ medical journals, said: "This study adds to the emerging evidence linking dietary patterns and mental health, raising important questions about whether restrictive diets which are low in nutrients considered beneficial for cognitive health, such as omega-3 fatty acids and vitamin B12, may precipitate depressive symptoms. Scientists explained that a "healthy" diet rich in fresh fruits and vegetables, whole grains, nuts, seeds, lean proteins and fish, is generally associated with a lower risk of depression. An "unhealthy diet" - dominated by ultra-processed foods, refined carbs, saturated fats, processed meats and sweets - has been linked to a heightened risk. Prof David Curtis, honorary professor at University College London, wo was not involved in the research, said: "The reported effects are small and some are scarcely statistically significant, so may well be due to chance. Even if it is the case that people who are dieting have more depressive symptoms, I don't see why we should assume that it is the dieting which causes this. "To me it seems plausible that this observation could be accounted for by the fact that people who are more unhappy with themselves, and with their weight in particular, may be more likely to go on a diet in an attempt to change their situation."
NBC News
11 hours ago
- NBC News
Two patients faced chemo. The one who survived got a test to see if it was safe.
JoEllen Zembruski-Ruple, while in the care of New York City's renowned Memorial Sloan Kettering Cancer Center, swallowed the first three chemotherapy pills to treat her squamous cell carcinoma on Jan. 29, her family members said. They didn't realize the drug could kill her. Six days later, Zembruski-Ruple went to Sloan Kettering's urgent care department to treat sores in her mouth and swelling around her eyes. The hospital diagnosed oral yeast infection and sent her home, her sister and partner said. Two days later, they said, she returned in agony — with severe diarrhea and vomiting — and was admitted. 'Enzyme deficiency,' Zembruski-Ruple texted a friend. The 65-year-old, a patient advocate who had worked for the National Multiple Sclerosis Society and other groups, would never go home. Covered in bruises and unable to swallow or talk, she eventually entered hospice care and died March 25 from the very drug that was supposed to extend her life, said her longtime partner, Richard Khavkine. Zembruski-Ruple was deficient in the enzyme that metabolizes capecitabine, the chemotherapy drug she took, said Khavkine and Susan Zembruski, one of her sisters. Zembruski-Ruple was among about 1,300 Americans each year who die from the toxic effects of that pill or its cousin, the IV drug fluorouracil known as 5-FU. Doctors can test for the deficiency — and then either switch drugs or lower the dosage if patients have a genetic variant that carries risk. The FDA approved an antidote in 2015, but it's expensive and must be administered within four days of the first chemotherapy treatment. Newer cancer drugs sometimes include a companion diagnostic to determine whether a drug works with an individual patient's genetics. But 5-FU went on the market in 1962 and sells for about $17 a dose; producers of its generic aren't seeking approval for toxicity tests, which typically cost hundreds of dollars. Doctors have only gradually understood which gene variants are dangerous in which patients, and how to deal with them, said Alan Venook, a colorectal and liver cancer specialist at the University of California-San Francisco. By the time Zembruski-Ruple's doctors told her she had the deficiency, she had been on the drug for eight days, said Khavkine, who watched over his partner with her sister throughout the seven-week ordeal. Khavkine said he 'would have asked for the test' if he had known about it, but added 'nobody told us about the possibility of this deficiency.' Zembruski-Ruple's sister also said she wasn't warned about the fatal risks of the chemo, or told about the test. 'They never said why they didn't test her,' Zembruski said. 'If the test existed, they should have said there is a test. If they said, 'Insurance won't cover it,' I would have said, 'Here's my credit card.' We should have known about it.' Guidance moves at a glacial pace Despite growing awareness of the deficiency, and an advocacy group made up of grieving friends and relatives who push for routine testing of all patients before they take the drug, the medical establishment has moved slowly. A panel of the National Comprehensive Cancer Network, or NCCN — specialists from Sloan Kettering and other top research centers — until recently did not recommend testing, and the FDA does not require it. In response to a query from KFF Health News about its policy, Sloan Kettering spokesperson Courtney Nowak said the hospital treats patients 'in accordance with NCCN guidelines.' She said the hospital would not discuss a patient's care. On Jan. 24, the FDA issued a warning about the enzyme deficiency in which it urged health care providers to 'inform patients prior to treatment' about the risks of taking 5-FU and capecitabine. On March 31 — six days after Zembruski-Ruple's death — the network's expert panel for most gastrointestinal cancers took a first step toward recommending testing for the deficiency. Worried that President Donald Trump's FDA might do nothing, Venook said, the panel — whose guidance shapes the practices of oncologists and health insurers — recommended that doctors consider testing before dosing patients with 5-FU or capecitabine. However, its guidance stated that 'no specific test is recommended at this time,' citing a lack of data to 'inform dose adjustments.' Sloan Kettering 'will consider this guidance in developing personalized treatment plans for each patient,' Nowak told KFF Health News. The new NCCN guidance was 'not the blanket recommendation we were working toward, but it is a major step toward our ultimate goal,' said Kerin Milesky, a public health official in Brewster, Massachusetts, who's part of an advocacy group for testing. Her husband, Larry, died two years ago at age 73 after a single treatment of capecitabine. European drug regulators began urging oncologists to test patients for deficiency in May 2020. Patients with potentially risky genetics are started on a half-dose of the cancer drug. If they suffer no major toxicity, the dose is increased. A lifesaving ultimatum? Emily Alimonti, a 42-year-old biotech salesperson in upstate New York, chose that path before starting capecitabine treatment in December. She said her doctors — including an oncologist at Sloan Kettering — told her they didn't do deficiency testing, but Alimonti insisted. 'Nope,' she said. 'I'm not starting it until I get the test back.' The test showed that Alimonti had a copy of a risky gene variant, so doctors gave her a lower dose of the drug. Even that has been hard to tolerate; she's had to skip doses because of low white blood cell counts, Alimonti said. She still doesn't know whether her insurer will cover the test. Around 300,000 people are treated with 5-FU or capecitabine in the United States each year, but its toxicity could well have prevented FDA approval were it up for approval today. Short of withdrawing a drug, however, U.S. regulators have little power to manage its use. And 5-FU and capecitabine are still powerful tools against many cancers. At a January workshop that included FDA officials and cancer specialists, Venook, the NCCN panel's co-chair, asked whether it was reasonable to recommend that doctors obtain a genetic test 'without saying what to do with the result.' But Richard Pazdur, the FDA's top cancer expert, said it was time to end the debate and commence testing, even if the results could be ambiguous. 'If you don't have the information, how do you have counseling?' he asked. Two months later, Venook's panel changed course. The price of tests has fallen below $300 and results can be returned as soon as three days, Venook said. Doubts about the FDA's ability to further confront the issue spurred the panel's change of heart, he said. 'I don't know if FDA is going to exist tomorrow,' Venook told KFF Health News. 'They're taking a wrecking ball to common sense, and that's one of the reasons we felt we had to go forward.' On May 20, the FDA posted a Federal Register notice seeking public input on the issue, a move that suggested it was considering further action. Venook said he often tests his own patients, but the results can be fuzzy. If the test finds two copies of certain dangerous gene variants in a patient, he avoids using the drug. But such cases are rare — and Zembruski-Ruple was one of them, according to her sister and Khavkine. Many more patients have a single copy of a suspect gene, an ambiguous result that requires clinical judgment to assess, Venook said. A full-gene scan would provide more information but adds expense and time, and even then the answer may be murky, Venook said. He worries that starting patients on lower doses could mean fewer cures, especially for newly diagnosed colon cancer patients. Power Should Rest With Patients Scott Kapoor, a Toronto-area emergency room physician whose brother Anil, a much-loved urologist and surgeon, died of 5-FU toxicity at age 58 in 2023, views Venook's arguments as medical paternalism. Patients should decide whether to test and what to do with the results, he said. 'What's better — don't tell the patient about the test, don't test them, potentially kill them in 20 days?' he said. 'Or tell them about the testing while warning that potentially the cancer will kill them in a year?' 'People say oncologists don't know what to do with the information,' said Karen Merritt, whose mother died after an infusion of 5-FU in 2014. 'Well, I'm not a doctor, but I can understand the Mayo Clinic report on it.' The Mayo Clinic recommends starting patients on half a dose if they have one suspect gene variant. And 'the vast majority of patients will be able to start treatment without delays,' Daniel Hertz, a clinical pharmacologist from the University of Michigan, said at the January meeting. Some hospitals began testing after patients died because of the deficiency, said Lindsay Murray, of Andover, Massachusetts, who has advocated for widespread testing since her mother was treated with capecitabine and died in 2021. In some cases, Venook said, relatives of dead patients have sued hospitals, leading to settlements. Kapoor said his brother — like many patients of non-European origin — had a gene variant that hasn't been widely studied and isn't included in most tests. But a full-gene scan would have detected it, Kapoor said, and such scans can also be done for a few hundred dollars. The cancer network panel's changed language is disappointing, he said, though 'better than nothing.' In video tributes to Zembruski-Ruple, her friends, colleagues, and clients remembered her as kind, helpful, and engaging. 'JoEllen was beautiful both inside and out,' said Barbara McKeon, a former colleague at the MS Society. 'She was funny, creative, had a great sense of style.' 'JoEllen had this balance of classy and playful misbehavior,' psychotherapist Anastatia Fabris said. 'My beautiful, vibrant, funny, and loving friend JoEllen.'
